Saroglitazar ameliorates alcoholic liver disease and is associated with enhanced ethanol metabolism

Figure 4 Effect of saroglitazar on liver aldehyde dehydrogenase 2 activity in therapeutic study design: Mice received saroglitazar or vehicle during a 4-week ethanol-feeding protocol. Liver samples were collected 9 hours after the ethanol binge to determine aldehyde dehydrogenase 2 activity using an enzyme-linked immunosorbent assay-based assay. It shows hepatic aldehyde dehydrogenase 2 activity expressed as mean ± SEM (n = 8 for normal control and n = 9 disease control and treatments). Statistical analysis was performed using one-way analysis of variance followed by Dunnett’s multiple comparison test. ^aP < 0.05, ^cP < 0.001 vs disease control group. PO: Orally; OD: Once daily; BID: Twice daily; UDCA: Ursodeoxycholic acid; ALDH2: Aldehyde dehydrogenase 2.